• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of postmedjPostgraduate Medical JournalVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
Postgrad Med J. Nov 2006; 82(973): 754–756.
PMCID: PMC2660504

Anthrax: a disease in waiting?

Abstract

Anthrax was a relatively unknown disease in the Western world until 2001, when spores were maliciously mailed in the US, causing five deaths. The mortality of the disease, the stability of its spores and the subsequent lack of person‐to‐person spread make anthrax an attractive biological weapon for terrorists with a desire for targeted mass destruction.

Anthrax is an ancient disease that is rarely seen outside well‐defined geographical areas, except as an occasional occupational hazard of animal hide handlers.1 Its current importance is its potential use for bioterrorism. One kilogram of Bacillus anthracis spores released over a crowded city of 10 million would cause >100 000 deaths despite antibiotic prophylaxis.2 Unlike other unfocused biological weapons such as smallpox or plague (which would spread unpredictably and involve associates of the liberators), anthrax does not spread from person to person and thus only the area that is attacked would effectively be made uninhabitable.

Pathogenesis

Anthrax is a disease of herbivores, especially ruminants. Humans are infected by contact with infected animals or by contact with animal products.1 Anthrax is initiated by spores that enter via small abrasions, or by inhalation or ingestion.3 These hardy spores are resistant to drying, heat, ultraviolet light, γ‐radiation and many disinfectants.4 In 1942, spores released experimentally on Gruinard Island, off the west coast of Scotland, persisted for 48 years4 and decontamination required 280 tons of formaldehyde and the removal of top soil.5 The final report at that time suggested that anthrax could be used to render cities uninhabitable “for generations”.6

After entering into the body, spores are carried by phagocytes to regional lymph nodes where they can become dormant, enter a vegetative state or enter the bloodstream.7 Vegetative bacteria secrete two exotoxins: oedema toxin and lethal toxin. Oedema toxin causes swelling of the affected areas by altering cellular cyclic AMP levels. Lethal toxin is responsible for evoking the release of tumour necrosis factor α and interleukin 1 by macrophages, and it is linked to shock and sudden death.8 Even if sterility of the bloodstream is maintained by antibiotics, high levels of lethal toxin can cause death.5

Bioweapon potential

The high death rate, spore persistence and restriction of infection to those exposed to it make anthrax an attractive bioweapon. The US military ran a biological weapon programme including anthrax until 1969.4 Accidental release of spores occurred in Sverdlosk in Russia in 1979.9 In September 2001, envelopes containing bioengineered B anthracis spores were mailed to several locations in the US.10 Eleven patients had cutaneous anthrax and of the eleven with inhalation anthrax, five died. Postal workers handling envelopes were probably infected via the airborne route. Four of those infected, who did not handle infected letters and had never been to buildings where infected letters were handled, presumably were infected by cross‐contamination. Overall, prophylaxis was offered to >10 000 people, including all postal workers in Washington, DC.11 Although adherence was poor (44%), no additional cases were reported.12

Clinical features

Anthrax occurs in three forms depending on where spores arrive.

Cutaneous anthrax occurs in 95% of natural infections and is generally an occupational disease of farmers (fig 11),), butchers, veterinarians and people processing animal products including wool, bones and hides.3 Once spores enter abrasions, a pruritic papule resembling an insect bite appears within 2–7 days. The papule then enlarges and develops vesicular elements (fig 22).). The rupture of vesicles occurs on days 5–7 with an eschar and much surrounding oedema.1,13 Symptoms such as eschar with oedema, painless lesions and lack of pus may help to differentiate it from other diseases (table 11).). Skin manifestations usually resolve slowly within 6 weeks, but a small proportion of the untreated patient may progress to systemic anthrax.1,8

figure pj44487.f1
Figure 1 Hand affected with Cutaneous anthrax (kindly supplied by Prof M Doganay, Kayseri Turkey).
figure pj44487.f2
Figure 2 Enlarged papule with formation of vesicular elements (kindly supplied by Prof M Doganay, Kayseri, Turkey).
Table thumbnail
Table 1 Differential diagnosis1,3,8

Gastrointestinal disease can develop if spores are ingested. Acute abdominal symptoms, including haematemesis, bloody diarrhoea and massive ascites may develop, mimicking food poisoning in the early stages and necrotising enteritis in severe cases.1 The prognosis for gastrointestinal disease is poor, with septicaemia and shock.8

Inhalation Anthrax is caused by spore inhalation. It is not a true pneumonia, as inhaled spores are transported to mediastinal lymph nodes to initiate haemorrhagic mediastinitis.8 A diagnosis of inhalation anthrax should raise the probability of a biological attack. The usual incubation period is 1–7 days, but spores can germinate much later than this—6 weeks in the Sverdlosk outbreak.9 The symptoms include rapid‐onset fever, chills, sweating, fatigue, minimally productive cough, nausea or vomiting and chest discomfort.10 The initial clinical presentation with non‐specific symptoms is similar to atypical pneumonia. Sore throat and rhinorrhoea are unusual and might help to differentiate inhalation anthrax from viral respiratory illnesses. Initial chest x‐rays show mediastinal widening, pleural effusion or pulmonary infiltrates.5 The disease progresses to the second stage in 2–3 days with further fever, dyspnoea, cyanosis and shock. In 2001, the death rate of inhalation anthrax cases was 45%, compared with 86% in the earlier Sverdlosk outbreak.9,10 This improvement might be related to the administration of more antibiotics, better supportive care and differences in host susceptibility.5,14 Patients with inhalation or systemic anthrax usually die rapidly, often before a definitive diagnosis can be made.

Diagnosis

B anthracis is easily isolated from blood cultures in <24 h.7 Swabs from a cutaneous lesion may be positive.1 Gram stains of peripheral blood, pleural effusion, ascites and cerebrospinal fluid (if meningitis is suspected) can disclose bacilli.3 Polymerase chain reaction of blood and sterile body fluids helps to diagnose patients who have received antibiotics.5,8

Management

B anthracis is susceptible to penicillin but given the possibility of bioengineered strains as seen in the US, parenteral ciprofloxacin or doxycycline in combination with another antibiotic is recommended.5,14

The duration of therapeutic or prophylactic treatment for inhalation anthrax is uncertain. Sixty days is recommended because spores can germinate weeks after inhalation.8,14 A vaccine is available for use in military settings.1

Conclusion

In the absence of a mass outbreak, most patients with cutaneous anthrax will be diagnosed because of occupational exposure. The early recognition of cutaneous anthrax by general practitioners will be pivotal and provide a diagnostic clue to other patients presenting with severe respiratory illnesses whose diagnosis might otherwise have to await postmortem examination. Prompt treatment and post‐exposure prophylaxis will be essential.

Footnotes

Competing interests: None declared.

Patient consent has been received for publication of the figures in this study.

References

1. Doganay M. Anthrax. In: Cohen J, Powderly WG, eds. Infectious Diseases 2nd edn. St Louis, MO: Mosby, 2004;1685–9,
2. Wein L M, Craft D L, Kaplan E H. Emergency response to an anthrax attack. Proc Natl Acad Sci 2003. 1004346–4351.4351 [PMC free article] [PubMed]
3. Turnbull P C B, Böhm R, Cosivi O. et al Guidelines for the surveillance and control of anthrax in humans and animals. Geneva: World Health Organization; 1998, http://www.who.int/csr/resources/publications/anthrax/WHO_EMC_ZDI_98_6/en/ (accessed on 12 September 2006)
4. Jacobs M K. The history of biologic warfare and bioterrorism. Dermatol Clin 2004. 22231–246.246 [PubMed]
5. Ingelsby T V, O'Toole T, Henderson D A. Anthrax as a biological weapon, 2002. Updated recommendations for management. JAMA 2002. 2872236–2252.2252 [PubMed]
6. BBC News Britain's “Anthrax Island”. 25 July 2001. http://news.bbc.co.uk/1/hi/scotland/1457035.stm (accessed on 12 September 2006)
7. Schwartz M N. Recognition and management of anthrax—an update. N Engl J Med 2001. 3451621–1626.1626 [PubMed]
8. Dixon T C, Meselson M, Guillemin J. et al Anthrax. N Engl J Med 1999. 341815–826.826 [PubMed]
9. Meselson M, Guillemin J, Hugh‐Jones M. The Sverdlovsk Anthrax Outbreak of 1979. Science 1994. 2661202–1207.1207 [PubMed]
10. Jernigan D, Raghunathan P L, Bell B P. et al Investigation of bioterrorism‐related anthrax, United States, 2001: epidemiologic findings. Emerg Infect Dis 2002. 81019–1028.1028 [PMC free article] [PubMed]
11. Centers for Diseases Control and Prevention Update: investigation of bioterrorism‐related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001. Morb Mortal Wkly Rep 2001. 50909–919.919 [PubMed]
12. Shepard C W, Gabarro M S, Zell E R. et al Antimicrobial postexposure prophylaxis for anthrax: adverse events and adherence. Emerg Infect Dis 2002. 81124–1132.1132 [PMC free article] [PubMed]
13. Wenner K A, Kenner J R. Anthrax. Dermatol Clin 2004. 22247–256.256 [PubMed]
14. Bell D M, Kozarsky P E, Stephens D S. Clinical issues in the prophylaxis, diagnosis, and treatment of anthrax. Emerg Infect Dis 2002. 8222–224.224 [PMC free article] [PubMed]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Group
PubReader format: click here to try

Formats:

Related citations in PubMed

  • Anthrax: what should the otolaryngologist know?[Acta Otolaryngol. 2002]
    Bradley PJ, Ferlito A, Brandwein MS, Benninger MS, Rinaldo A. Acta Otolaryngol. 2002 Sep; 122(6):580-5.
  • Anthrax: a review.[J Med Liban. 2003]
    Kanj SS, Kanafani ZA, Ghossain A. J Med Liban. 2003 Jan-Mar; 51(1):29-37.
  • [The ABCs on anthrax for health personnel].[Salud Publica Mex. 2001]
    Valdespino-Gómez JL, García-García ML. Salud Publica Mex. 2001 Nov-Dec; 43(6):604-13.
  • Anthrax infection.[Am J Respir Crit Care Med. 2011]
    Sweeney DA, Hicks CW, Cui X, Li Y, Eichacker PQ. Am J Respir Crit Care Med. 2011 Dec 15; 184(12):1333-41. Epub 2011 Aug 18.
  • [Anthrax].[Recenti Prog Med. 2001]
    Calza L, Manfredi R, Chiodo F. Recenti Prog Med. 2001 Dec; 92(12):717-26.
See reviews...See all...

Cited by other articles in PMC

See all...

Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...